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       “Learning without thinking is of no use. 
           Thinking without learning is dangerous.” 
                       (Confucius) 
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1. Introduction  
 
1.1 Prematurity and its complications 
 
Prematurity is defined as birth before 37 weeks of gestation and may be grouped 
according to either weight or gestational age (Tab. 1, 1). 
 
Table 1. Subgroups in the premature population and their frequency in the total number of births in 
Norway in 2009 (2) 
 
Over the last five decades a picture of decreasing mortality has emerged for all groups of 
premature infants (Fig. 1, 3). The application of early intubation and more sophisticated 
fetal monitoring, the introduction of surfactant treatment and the use of incubators 
stabilizing the environment, the introduction of prenatal GC treatment of mothers in the 
1990s are some of the factors behind this positive trend (4, 5).  
The mortality of the extreme preterm group can also vary between hospitals and 
countries. For babies with birth weight 600-699 grams mortality ranges from 27 to 63 
% in centers in industrialized countries (5, 6).  
Advances in minimal invasive treatment and nursing (Newborn individualized 
Developmental Care and Assessment Program - NIDCAP, 7) have reduced environmental 
stress factors like pain sensations because of frequent blood tests and unpleasant 
auditory sensations because of frequent alarms on the neonatal intensive care unit.       
 
 
 
 
Low birth weight (LBW)/ 
Moderately preterm 
1500 - 2500 grams  
32 - 37 gestational weeks  
   2526                    4,1% 
Very low birth weight (VLBW)/ 
Very preterm 
1000 -1499 grams  
28 – 32 gestational weeks 
    343                      0,6% 
Extremely low birth weight (ELBW)/ 
Extremely preterm 
500 - 999 grams  
22 - 27 gestational weeks 
    235                      0,4% 
                
Total number of births in Norway in 2009  62213                100% 
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Figure 1. Mortality rates for preterm infants born with birth weight 501-750 grams, 751-1000 and 1001-
1500 respectively from 1951 to 2000 according to a Rawlings et al., single center study (8),  bHack et al., 
single centre study (4),  cFanaroff et al. 2003, multicenter study, NICHD network  (3). (The definition of 
neonatal mortality varies in the three studies, see reference.) 
 
 
 
 
1.1.1 Morbidity associated with premature birth 
 
Morbidity of the preterm child in the postnatal period (28 days after birth) involves 
most organ systems (Tab. 2).  
Treating the extreme low birth weight infant is challenging. The patient may need 
intubation, artificial ventilation and total parental nutrition in the initial period of 
treatment, and intensive care is needed over several weeks to months. Nevertheless, 
even with recent advances in treatment the prevalence of bronchopulmonary dysplasia 
(BPD), necrotizing enterocolitis and severe intraventricular hemorrhage remains 
relatively stable in recent cohorts (1995-2000) of preterm infants with BW < 1500 
grams (9).   
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Morbidity Frequency for 501-1500 
grams of birth weight 
Growth failure 91 
Respiratory distress syndrome 44 
Patent ductus arteriosus 29 
Intraventricular hemorrhage 27 
Late onset septicemia 22 
Bronchopulmonary dysplasia 22 
Necrotizing enterocolitis 7 
Pneumothorax 5 
Periventricular leukomalacia 3 
Table 2. Preterm morbidity for birth weight 501-1500 grams adapted from Fanaroff et al. 2007 (9), 
Growth failure: <10th percentile at 36 weeks postconceptual age 
 
 
1.1.2 Long term consequences of prematurity 
 
Several studies have found that prematurity is associated with significantly lower height 
and weight as well as lower head circumference in early childhood and even into young 
adulthood associated with prematurity (10, 11, 12). The main focus in long term follow 
up after premature birth has been on impaired neurodevelopment and its consequences 
for cognitive, motor, neurosensory, behavioral and functional outcome. According to a 
Swedish cohort study from 1959 to 2002 (13, 14) the prevalence of cerebral palsy, a 
non-progressive disorder of movement and posture as a result of an injury to the 
immature brain, has slightly increased (Fig. 2) for all groups. The most recent cohort 
(1999-2002) showed, though, a significant decrease in CP for the ELBW group, 
compared to the previous cohort (1995-1998). Other studies have reported similar 
findings (15). The recent increase in CP for the term born cohort mainly accounted for 
the general increase in CP in the Swedish study group. It was speculated that this 
increase was caused by an increasing survival of term babies suffering from hypoxic-
ischemic encephalopathy, an injury of the brain caused by hypoxia and ischemia ante- 
and intrapartum (14).  
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Figure 2. Prevalence of cerebral palsy in a Swedish population according to Himmelmann et al. (14), CP 
cerebral palsy 
 
The incidence for other disabilities such as mental retardation, epilepsy, blindness and 
moderate to severe hearing impairment has been rather stable over the past 20 years 
(5). A cohort study of all live born individuals from 1967-1983 in Norway concluded 
that gestational age at birth was inversely correlated to the incidence of cerebral palsy, 
mental retardation, autism spectrum disorders as well as other psychological or 
psychiatric disorders (16). The total disability rate was highest in the ELBW group. 
Preterm birth was also associated with lower levels of education, lower job income, and 
reduced probability to have children and be married, even in the absence of a major 
medical disability. This association was also found in other studies of social outcomes of 
prematurity (17).   
Recent studies of preterm infants of birth cohorts born in the 1990’s show reduced 
school performance and lower IQ (18, 19, 20, 17) indicating that subnormal 
neurodevelopment is persisting even in the newer cohorts. Recent cohort studies did 
not include postnatal GC treatment in their analysis of confounding factors.  
There is also evidence that prematurity might be associated with other major disease 
complexes in adulthood, such as hypertension and diabetes type II (21, 22).  
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1.1.3 GC regulation and the preterm infant 
 
GCs are secreted from the adrenal gland and are called “stress hormones”. GCs were 
found to have a vital role in maintaining processes like salt regulation, blood pressure 
and temperature regulation. Adrenalectomized patients died without substitution of GCs 
(23). Later, the connection between stress and amelioration in autoimmune disease or 
allergy was recognized (24). GC treatment in autoimmune disease led to the discovery of 
a range of side effects on different organs such as changes in glucose and insulin level, 
bone, fluid and electrolyte balance and depression.  
The existence of a distinct feedback mechanism for regulation of the glucocorticoids 
(GCs) in connection with stress, the hypothalamic-pituitary-adrenal axis (HPA axis) was 
first described of H. Selye (25). The paraventricular nucleus of the hypothalamus 
produces corticotropin releasing factor (CRH), which in turn promotes release of 
adrenocorticotropic hormone (ACTH) from the anterior part of the pituitary. ACTH 
reaches the adrenal gland and releases GCs from the outer zone. GCs in turn block the 
release of ACTH through a negative feedback mechanism on proopiomelanocortin 
(POMC), the precursor of ACTH. Studies in rat show evidence for a non-functioning GC 
homeostasis in fetal life. High levels of circulating steroids fail to downregulate 
glucocorticoid receptor (GR) in the fetal brain, thereby leaving it more vulnerable to 
excess GC levels occurring in stressful situations (26). Studies of animals and human 
fetuses in the last term of gestation showed that GC production increases near 
parturition (27) and is necessary for parturition, as ablation of the fetal paraventricular 
nucleus (production of CRH) leads to prolonged gestation (28, 29).  
The fetal HPA axis is repressed by maternal hydrocortisone (HC, also called cortisol and 
the predominant GC in humans) circulating in the fetus. In late pregnancy increasing 
11β-hydroxysteroid dehydrogenase 2 levels in the placenta lead to inactivation of 
maternal HC and liberate the fetal axis to produce GCs. In extreme preterm birth the 
infant is parted from the provider of HC and the immature adrenal gland is not able to 
produce enough HC.  Thus a relative adrenal insufficiency is present in premature 
infants (30). 
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1.2 Glucocorticoid (GC) treatment in premature infants and long-term 
neurodevelopmental consequences 
 
Experimental pharmacological treatment of premature infants for the prevention of 
neonatal respiratory distress syndrome (RDS), characterized by respiratory distress, 
increasing oxygen requirement and diffuse reticular-granular infiltrates as well as 
atelectasis on chest x-ray, started in the 1950s. Studies from this era showed no clear 
treatment effect of GCs on RDS, but most studies included only small numbers of treated 
individuals (31, 32). In a large study 135 infants were included but there was no control 
group established (33).  
Based on experiments on prenatal lung development in lamb Liggins and Howie (34) 
suggested that prenatal treatment with highly potent GCs might accelerate lung 
maturation. Their later clinical ”trial of ante partum glucocorticoid treatment for 
prevention of RDS in premature infants” (35) was the first that could show significantly 
reduced incidence of RDS in preterm babies of mothers treated with 12 mg 
betamethasone when compared to preterm babies of mothers treated with 6mg 
cortisone (Cort). Cort has a 70 times lower GC potency than betamethasone and served 
as control substance. Subsequently several controlled studies confirmed these results 
(Roberts D 2010, Fig.3). A first systematic review in 1990 concluded that antenatal GC 
treatment resulted in substantially reduced neonatal mortality and morbidity (36). 
Finally this lead to general recommendations and international guidelines for steroid 
use in treatment of preterm infants (37, 38).  
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Figure 3. Meta-analysis of risk ratio for RDS with antenatal GC treatment according to Roberts et al. 2010 
(39). RDS risk ratio for individuals treated with antenatal GCs compared to controls is listed for 21 studies. 
Total risk ratio and test for overall treatment effects are highlighted (red). 
 
 
Risk assessment for cerebral palsy in childhood showed a decreased risk with antenatal 
GC treatment (39). 
With the survival of more preterm infants a new disease entity emerged: 
bronchopulmonal dysplasia (BPD) characterized by pulmonal interstitial fibrosis, 
pulmonary opacities on x-ray and oxygen dependency at 36 gestational weeks. 
Eventually BPD was linked to a combination of factors: prematurity, mechanical 
ventilation, high oxygen exposure and inflammation. The inflammation hypothesis 
prompted studies that used GCs for the postnatal prevention of BPD (for review see 40, 
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and Fig. 4A, 41 and Fig 4B). Reduced risk for BPD was found with early and late Dex 
treatment, but not HC treatment.   
 
 
Figure 4A. Meta-analysis of risk ratio for BPD at 36 weeks in survivors with early (<8 days) GC treatment 
according to Halliday et al. 2009 (40). BPD risk ratio for individuals treated with postnatal Dex or HC 
compared to controls is listed for 18 studies. Total risk ratio and test for overall treatment effects are 
highlighted (red). 
 
 
 
  
HC 
Dex 
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Figure 4B. Meta-analysis of risk ratio for BPD at 36 weeks in survivors with late (>7 days) GC treatment 
(Dex only) treatment according to Halliday et al. 2009 (41) BPD risk ratio for individuals treated with 
postnatal Dex compared to controls is listed for 4 studies. Total risk ratio and test for overall treatment 
effects are highlighted (red). 
 
 
The Cochrane Collaborative Study Group also summarized the relative risk for cerebral 
palsy estimated by randomized controlled clinical studies of early (<8 days) postnatal 
GCs (40) and late (>7 days) postnatal GC treatment for the prevention of BPD (41). Early 
treatment (< 8 postnatal days) of premature infants was found to give an increased risk 
of cerebral palsy (Fig 5A, 40). Dexamethasone (Dex) treatment accounted for the 
increased risk ratio (1,82) alone whereas HC treatment showed no increased risk ratio 
for CP in survivors (0,95). Late treatment (>7 days of age) with GCs (only Dex used) did 
not change the cerebral palsy risk rate significantly (Fig. 5B, 41) thereby indicating that 
GC damage to the brain may be more significant at an early developmental stage.   
A randomly controlled trial by Yeh et al. (42) on preterm infants treated with Dex for 
BPD in 28 days postnatal showed significantly reduced IQ and motor skills at school age 
compared to preterm controls, who were not treated with Dex.  
Guidelines from the American Academy of Pediatrics, the Canadian Paediatric Society 
and the European Association of Perinatal Medicine have since concluded that postnatal 
GC should be avoided in the first 4 postnatal days and should be reserved for the 
treatment of the sickest preterm infants dependent on ventilator (43). 
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Figure 5A: Meta-analysis of risk ratio for CP in survivors with early (<8 days) GC treatment according to 
Halliday et al. 2009 (40). CP risk ratio for individuals treated with postnatal Dex or HC compared to 
controls is listed for 18 studies. Total risk ratio and test for overall treatment effect are highlighted (red). 
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Figure 5B: Meta-analysis of risk ratio for CP in survivors with late (>7 days) GC treatment assessed at age 
1-3 according to Halliday et al. 2009 (41). CP risk ratio for individuals treated with postnatal Dex 
compared to controls is listed for 18 studies. Total risk ratio and test for overall treatment effect are 
highlighted (red). 
 
 
 
1.3 The need for animal models in the study of GC effects in immature 
organisms 
 
Several animal models have been developed to study the effects and side effects of 
antenatal GC administration. Animal models are needed in the study of these effects 
because the evaluation of basic toxicological mechanisms such as apoptosis, 
proliferation and differentiation in the brain as a result of GC treatment cannot be 
accomplished in humans. Moreover, as the premature infant undergoes intensive 
treatment and might be affected by various morbidities (see section 1.1.1), it is 
obviously important to distinguish GC effects from other consequences of prematurity 
which may only be achieved in animal models to a sufficient degree (44, 45).   
A large body of initial experimental work was done in sheep. Liggins et al. (34) were the 
first to test Dex as initiator of premature labor and observed partial aeration in the 
alveolar tissue of some newborn lambs of mothers treated with GCs. In subsequent 
studies single and repeated doses of prenatal administered GC increased lung 
compliance and surfactant protein B mRNA (46, 47). Studies in rhesus monkeys 
confirmed results from sheep studies (48).  
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A number of studies found reduced birth weight (46, 49, 50) Several studies show 
reduced brain weight with GC treatment. Table 3 summarizes results of representative 
experimental studies on how GC treatment affects brain size and structures.  Permanent 
degeneration of pyramidal neurons in the hippocampus and to a lesser degree in other 
cortical regions in rhesus monkeys treated with a single dose or repeated doses of Dex 
in utero have been reported by Uno et al. (51). Increased apoptosis of neural progenitor 
cells and immature neurons in the hippocampus was shown in rat pups postnatal 
treated with Dex (52). 
Cotterell et al. (53) found that cell proliferation in rat brain and especially in rat 
cerebellum was blocked by HC (approx. 40mg/kg) in rats. GC treatment of neonatal rats 
showed a permanent reduction of cell number in the adult cerebellum  (54). Postnatal 
Dex treatment of mice resulted in a transient increased apoptosis of neural progenitor 
cells in the external granular layer (EGL) of the cerebellum (55).  
Howard et al. (56) showed that Cort treatment caused reduced cerebellar size and “a 
lasting impairment in fine adjustment mechanisms of motor control” in mice.  
Ahlbohm et al. (57) showed that cerebellar granule neuron cultures from one-week old 
rat pups treated with Dex in pregnancy showed an impaired mitochondrial function and 
higher sensitivity to oxidative stress.  
However, detailed molecular mechanisms for GC effects on cell death, proliferation and 
differentiation in the immature nervous system are still largely unknown. 
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Anatomical 
structure 
Animal/study GC 
administration 
Effect 
Whole brain Mouse (58) Cort postnatal Decreased DNA content in adult mice 
Whole brain 
 
Rat (53) HC postnatal Weight reduction and inhibition of 
proliferation in whole brain 
Total cell reduction in cerebrum  
Whole brain 
 
Rat (59) Dex in high/low 
dose postnatal 
High dose: Permanent weight reduction in 
young adults 
Low dose: Transient weight reduction in young 
adults  
Both doses: impaired acquisition of spatial 
learning 
Whole brain Lamb (60) Betamethasone 
(Bet) antenatal 
to fetus 
No weight reduction 
Whole brain Lamb (50) Bet antenatal Weight reduction 
Whole brain  
 
Lamb (61) Bet antenatal Weight reduction at term  
Whole brain Rat (62) Dex postnatal Weight reduction 
Delay in gross neurologic development 
Hippocampus 
Dentate 
gyrus 
Rhesus monkey 
(51) 
Dex antenatal Decreased number of hippocampal pyramidal 
cells and granule neurons in dentate gyrus in 
newborns 
Dentate 
gyrus 
Common marmoset 
monkey (63) 
Dex antenatal Reduced proliferation and normal 
differentiation 
Dentate 
gyrus 
Common marmoset 
monkey (64) 
Dex antenatal No volume difference, reduction of 
proliferation or increased differentiation in 
adult animal 
Hippocampus Rat (52) Dex postnatal Increased apoptosis of neural progenitor cells 
and immature neurons in the hippocampus 
Optic nerve Lamb (65) Bethametasone 
antenatal 
Reduction of myelination in preterm lamb 
delivered by cesarean section 
Cerebellum Mouse (58 
 
Cort postnatal Weight reduction in adult mice.  
Decreased DNA content in adult mice 
Impairment in fine adjustment mechanisms of 
motor control 
Cerebellum Rat (53) HC postnatal Total cell reduction  
Cerebellum, 
external 
granular 
layer (EGL)  
Rat (54) HC postnatal Cell reduction and early disappearance of the 
EGL in pups 
Cell reduction in adult animals 
Cerebellum 
 
Rat (59) Dex in high/low 
dose postnatal 
High dose: Permanent weight reduction in 
young adults 
Low dose: Transient weight reduction in young 
adults  
 
Cerebellum 
 
Lamb (61) Bet antenatal Weight reduction at term  
Cerebellum, 
EGL  
Rat (57) Dex antenatal Higher sensivity to oxidative stress and 
impaired mitochondrial function in granule cell 
cultures from one-week old rat pups  
Cerebellum, 
EGL  
Mouse (55) Dex postnatal Transient apoptosis in neural progenitor cells 
Cerebellum, 
internal 
granular 
layer (IGL) 
Paper 2 and 4 Dex/HC 
antenatal 
Increased apoptosis in the IGL, decreased 
proliferation and increased differentiation of 
cerebellar granule neurons in the IGL  
Table 3. Representative animal model studies of GC effects on the immature brain 
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1.4 The developing cerebellum as model structure for the study of GC effects  
 
GC treatment of mice showed strongest effect on cell numbers in the cerebellum in one 
early study (58). During normal development DNA content (representing cell content) 
increased about 25 % in postnatal mouse cerebrum, whereas the cerebellum multiplied 
its cell amount by approximately a factor of six (58). Cort treatment reduced the DNA 
amount in the cerebellum by 25% compared to 10% in cerebrum. Thus the cerebellum 
was the structure with the greatest structural changes on GC treatment. Cell birth, cell 
death and differentiation can be easily monitored. Both animal studies and clinical trials 
report effects on motor regulation (56, 42), thereby pointing to the cerebellum as a 
relevant model structure for the study of GC effects. 
The avian cerebellum is organized in 10 folia (66). Early in development the cerebellum 
starts to form from the anterior-most rhombomere (a transiently divided segment in the 
hindbrain region of the embryo, that later becomes the rhombencephalon), 
rhombomere 1, as part of the metencephalon that engulfs the bottom of the fourth 
ventricle. The cerebellar structures expand dorsally and fuse to the dorsal area then 
outlining the roof of the fourth ventricle (Fig. 6, 67).  
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Figure 6. Early development of the cerebellum at about 4 weeks of development (a), at the end of the 
embryonic period (b) and at 13 weeks of development (c) according to ten Donkelaar et al. 2003 (67); 
The V-shaped tuberculum cerebelli is shown in gray, and the upper and lower rhombic lips by vertical and 
horizontal hatching, respectively. In c, open arrows show the migration paths from the rhombic lips. cbi 
internal cerebellar bulge; ci colliculus inferior; Cpb corpus pontobulbare; cs colliculus superior; is isthmus; 
mes mesencephalon; nV trigeminal nerve; tbac tuberculum acusticum; tbcb tuberculum cerebelli; tbpo 
tuberculum ponto-olivare; 2, 4, 6: rhombomeres. 
 
Important for cerebellar development is the isthmus organizer, a patterning centre at 
the midbrain-hindbrain boundary. Genes in this region encode transcription factors 
Otx2 and Gbx2. Otx2 is expressed in the midbrain and Gbx2 promotes development of 
the hindbrain through a mechanism involving transcription factors Wnt1 and Fgf8 (68).  
Precursors for different neuron types migrate to the their regions of destiny. Precursors 
to glutaminergic neurons originating from the rhombic lip differentiate under the 
influence of Math1, a transcription factor, into granule cells, unipolar brush cells and 
deep nuclear projection neurons (blue cell in Fig. 7, 68).  
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Figure 7. The different neuron types of the cerebellum and their origins according to Carletti et al., 2008 
(68).   
All cerebellar phenotypes derive from two germinative neuroepithelia: the ventricular zone (VZ, green) 
and the rostral half of the rhombic lip (RL). The Math1-expressing progenitor cells of the RL give rise to all 
types of glutamatergic neurons of the cerebellum (deep nuclear 69 projection neurons, unipolar brush 
cells UBC and granule cells). The VZ contains progenitor cells expressing the transcription factor Ptf1a 
including nucleo-olivary projection neurons, Purkinje cells, and inhibitory interneurons. RL rhombic lip; 
VZ ventricular zone; UBC unipolar brush cell; DN deep nuclear; ML molecular layer; GL granule layer, IV 
fourth ventricle. 
 
Granule neurons migrate tangentially to the surface of the cerebellum and generate the 
EGL. The EGL is a temporary structure that disappears as precursor cells from this 
region migrate inwards into the internal granular layer (IGL). This process ends in 
chicken about 10 days post hatching and in man up to 2 years after birth and eventually 
a three layered structure is reached from outward to inward comprising the molecular 
layer (ML), the Purkinje cell layer (PL) and the granular layer (Fig.8). Precursors to 
gabaergic neurons originating from the ventricular zone differentiate under the 
influence of the transcription factor Ptf1A into Purkinje cells, Golgi and Lugaro cells and 
deep nuclear interneurons (green cells in Fig.7). Differentiation of granule cell precursor 
into mature granule cell is regulated by Sonic hedgehog (Shh), a morphogen secreted by 
Purkinje cells (70, 71). 
Purkinje cells migrate to a layer between the IGL and the molecular layer, which 
contains the expanding dendritic tree of Purkinje cells and their connections from 
granule cells and interneurons.  
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Figure 8. Schematic 3D view of the cerebellar cortex with its connections according to Colin et al. 2002 
(72) 
 
It is mostly unclear which factors promote differentiation of gabaergic neuronal 
precursors into Purkinje cells and other neuronal cell types. The hypothesis that 
inductive signals come from the rhombomere 1 roof plate awaits confirmation (73).  
 
1.4.1 Apoptosis as a naturally occurring phenomenon in the developing 
cerebellum 
 
Naturally occurring cell death is an integral part of normal development (74).  
Cell death by apoptosis was first defined by histological criteria of cell condensation, 
eosinophilic cytoplasm and condensation and fragmentation of the nucleus (75). The 
executioner proteins of apoptosis, the caspases, were first discovered in Caenorhabditis 
elegans. Pro- and anti-apoptotic proteins were also found in this model, and homologues 
were later identified in mammals. Apoptosis can also occur without involvement of 
effector caspases (76).  
Apoptosis is initiated through an extrinsic or an intrinsic pathway (Fig. 9, 77). The 
extrinsic pathway involves death receptors like the tumor necrosis factor superfamily of 
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death receptors on the cell surface, including FAS, which on binding of a ligand forms a 
death-inducing signaling complex that activates caspase-8. Caspase-8 then activates 
other caspases, among them caspase-3, -6 and -7 that are responsible for inducing the 
ultrastructural changes in apoptosis. An array of other apoptotic stimuli, among them 
GCs and chemotherapeutic agents, leads to activation of the intrinsic pathway, which 
involves intracellular proapoptotic proteins like Bax and Bim. Bax forms pores in the 
mitochondrial membrane through which cytochrome c, one of the enzymes of the 
respiratory chain, can be released to the cytoplasm. Here it binds to Apaf-1 and caspase 
9 in an apoptosome, which activates the common pathway of effector caspases 3, 6 and 7 
resulting in microscopically visible morphological changes in the cell.    
 
Figure 9. Apoptotic pathways according to Joza et al., 2002 (77) 
The “extrinsic pathway” starts with the binding of ligand to a death receptor e.g. Fas. Fas then initiates 
recruitment of FADD and caspase-8 to the cytoplasmic regions of the receptor. Caspase-8 activates 
terminal caspases-3, -6 and -7. In response to endogen death stimuli e.g. GCs, distinct ‘BH3-only’ proteins, 
such as Bid and Bim, get activated in the “intrinsic pathway”. BH3-only proteins subsequently translocate 
to mitochondrial surfaces, where they associate with Bcl-2 protein. Anti-apoptotic Bcl-2 family members 
(e.g. Bcl-2, Bcl-XL) are inactivated, and pro-apoptotic Bcl-2 members potentially form mitochondrial pores 
or interact with pre-existing membrane channels. Release of cytochrome c (cyt c) induces formation of the 
apoptosome in association with Apaf1 and caspase 9. The apoptosome then activates effector caspases 3, 
6 and 7. AIF induces hallmarks of apoptosis independent of caspases.  
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Apoptosis in the nervous system may serve different purposes like removal of non-
functional cells, removal of neurons with erroneous connections and removal of 
superfluous cells (74). It is assumed that about 50% of all generated neurons in the CNS 
undergo apoptotic death in development. In several regions of the brain apoptosis 
occurs in two phases: first at the onset of neurogenesis and migration and later 
connected to synapse formation between differentiated neurons (78, 79). 
Studies of apoptosis in the cerebellum have concentrated on granule cells as their 
abundance and high developmental turnover allows the quantification of apoptotic 
profiles. 
Both premigratory granule cells in the EGL and postmigratory cells in the IGL are 
affected by cell death (79, 55). Premigratory granule cells and neuronal progenitor cells 
undergo apoptotic death mainly because of the deficiency of morphogen Shh or growth 
factors like brain derived neurotrophic factor (70, 80). Postmigratory granule cells have 
been proposed to undergo apoptosis as a consequence of competition for synapse 
formation with other cells (80). 
Purkinje cell death is estimated to occur in half of the originally generated neurons and 
occurs early in development during two phases in rodent cerebellum, around embryonic 
day 12 and directly postnatally (81, 82). Quantification of Purkinje cells after postnatal 
day 4 shows no further loss (83).   
Genetic conditions, chemical substances and environmental factors can influence 
cerebellar development. Reduced cerebellar size and neuronal loss are associated with 
autosomal recessive ataxias and syndromes like Rett syndrome (X-linked deletion of 
methyl-CdP-binding protein 2, 84) in humans and mice. About 25 different genetic 
mutations in mice that cause cerebellar dysfunction including ataxia or neuronal loss 
have been described as harlequin, hoxc-8, lurcher, purkinje cell degeneration, and weeble 
mutants (www.informatics.jax.org). In other phenotypes like stumbler, meander tail and 
flathead the genetic defect is not defined yet.  
Cerebellar apoptosis can be affected by different agents, e.g. ethanol (85), anticancer 
drugs e.g. cytosine arabinoside (AraC, 86), thyroid hormone (87, 88), and GCs (paper 2, 
89).  
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1.4.2 Proliferation and differentiation in the developing cerebellum 
 
Genes Pax 2, Wnt 1 and En1 regulate initialization of cerebellar growth. Pax 2, Wnt1 and 
En1 knockout mice do not develop a cerebellum at all (90), whereas transcription factor 
Math1 knock out mice do not develop an EGL (91). Other impairments in protein 
function like a dysfunctional retinoid-like orphan receptor α are known to reduce the 
external granule layer profoundly and a mutation in the gene coding for this receptor 
creates the characteristic phenotype staggerer (92). The granule cells of the vertebrate 
cerebellum proliferate during development until long after birth in all vertebrate 
species. The end of the proliferation period is visible by the disappearance of the EGL.   
Cells that arrest in G1 (Fig. 10) await various fates such as differentiation, apoptosis, 
quiescence (cells in this state do not enter the cell cycle, are smaller in size and have 
lower metabolism) and senescence (cells leave the cell cycle irreversibly), the latter two 
representing resting states of the cell. Differentiation often leads to an irreversible 
specialization of the cell.   
 
Figure 10. Protein complexes of cell cycle regulator proteins called cyclins tightly regulate the cell cycle 
and cyclin-dependent kinases (CDK) Cells start replication in G1. In S phase chromosomes are synthesized 
such that a double chromosome set is generated. In G2 chromosomes migrate to their poles and in M 
phase the cells divides into to daughter cells (mitosis). During each of the four phases of the cell cycle a 
specific protein complex has to form in order for the cell to progress to the next phase (93).   
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The exact steps that lead to different cell types into different states are mostly unclear. 
To date some proteins have been defined that can promote differentiation. Cyclin-
dependent kinase inhibitor p21WAF1 expression in the PC12 pheocromocytoma cell line 
leads to differentiation of PC12-cell into neurons. Cyclin-dependent kinase inhibitors 
might present a link to the mechanisms that promote neuronal differentiation by 
arresting cells in G1 phase (94). Mice with a deletion of another cyclin-dependent kinase 
inhibitor p27 have larger cerebella and extended cell cycle in the EGL. P27 is specifically 
expressed in cells within the inner EGL (95) indicating that it might have a role in 
proliferation control and differentiation for granule neurons. Interestingly, GCs have 
been found to upregulate p27 translation in non-neuronal cell types like breast cancer 
cells (96), osteoblasts (97) and stimulated lymphocytes (98).   
During the development of the cerebellum granule cells replicate intensely. Purkinje 
cells secrete Shh, a ligand to the receptor Patched. Patched is located in the cell 
membrane of granule cells (70). On ligand binding, Patched will promote expression of 
genes like Nmyc and Cyclin D1, which leads to replication of the cell. Shh can prevent 
death of cerebellar granule cells induced by HC but not when death is induced by Dex by 
upregulating 11β-HSD2 (99). Other growth factors e.g. insulin-like growth factor 1 
(100), basic fibroblast growth factor (101) or brain-derived neuronal growth factor 
(102) are known to increase proliferation in the cerebellar neuronal population.  
Lately another protein called REN has gained attention with respect to regulation of 
proliferation and differentiation. The deletion of this gene was discovered in 
medulloblastoma, which is a tumor originating in immature granule cells of the 
cerebellum (103). In further studies it was shown that REN is expressed in granule 
neurons on the inner rim of the EGL and in the IGL. Overexpression leads to reduced 
Bromdeoxyruridine (BrdU) incorporation and increased Neuronal Nuclei (NeuN) 
protein expression in cultured granule neurons thus showing promotion of 
differentiation (104). REN could also be shown to counteract the Shh pathway. 
Changes in cell proliferation and differentiation in the cerebellum are associated with 
syndromes like the different autosomal recessive ataxias and Rett syndrome in humans 
and mice (X-linked deletion of methyl-CdP-binding protein 2, 84). Different agents like 
ethanol, nicotine (105), and thyroid hormone (106) can also disturb birth and 
maturation of granule cells and other neurons. 
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1.5 The cerebellum and its role in motor control and higher brain functions 
 
The cerebellum is through the inferior, middle and superior peduncle connected to 
different parts of the spinal cord and olive, vestibular organ, motor cortex, dorsal 
prefrontal areas and extrapyramidal system (107).  
Holmes has described characteristic symptoms of voluntary and involuntary motor 
control as a consequence of cerebellar damage in man as early as in 1939 (108). They 
comprise abnormalities in the rate, regularity and force of voluntary movements, 
postural hypotonia, and a mild degree of asthenia and fatigability of the muscles. Others 
have shown that ablation of the cerebellum leads to loss of learned motor sequences 
(109). Later disordered eye movements (nystagmus), poor articulation (dysarthria), 
impaired swallowing and tremor were also recognized as symptoms of cerebellar 
affection (110). 
It is striking that only a fraction of the total cerebellar area is occupied with motor 
control. It has been proposed that other regions may be involved in control of higher 
brain functions. Indeed, functional imaging has shown that some cerebellar lesions give 
rise to impairment of verbal working memory (the ability to name a list of digits 
backwards after they have been named, 111, 112). 
The concept of a “cerebellar cognitive affective syndrome” proposed by Schmahmann et 
al. (110) is characterized by disturbances of executive function (deficient planning and 
abstract reasoning), impaired spatial cognition, personality change (flattening of affect), 
and linguistic difficulties (dysprosodia, agrammatism) both in adults and children with 
cerebellar damage of variable origin. The connection of the cerebellum with dorsal 
prefrontal areas responsible for planning activities may represent the anatomic 
correlate to disturbances in higher brain functions, especially executive functions (107).  
Interestingly, postmortem analysis of cerebellar changes in autism cases has reported 
cerebellar changes in 54%, predominantly flocculonodular dysplasia, thus linking the 
cerebellum to autism (113).  
 
1.6 Nuclear receptors (NRs) 
 
Effects of hormones on DNA were first noted by Clever et al. (114), who experimented 
with the insect steroid hormone ecdysone and saw changes on the giant chromosomes 
of Chironomus tentans, a non-biting midge, upon treatment. The human GR and the 
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estrogen receptor (ER) were the first NRs to be cloned and expressed in 1985 (115, 
116). Subsequent sequencing of NRs demonstrated the general structural organization 
principle of the NR (Fig. 11, 117) 
 
Figure 11. General structure of NRs according to Beato M, 1989 (117). Hsp heat shock protein 
The basic structure is divided into 4 main regions: the N-terminal region (A/B), the DNA binding region 
(C), the adjacent central region, also called hinge region (D) and the ligand-binding region (E). D and E are 
involved in nuclear translocation together with C. All regions are involved in transactivation (modulation 
of transcription). Some nuclear response elements require dimerization of the receptor. Dimerization is 
mainly involving E with modulation of C and D. Hsp90 binds to E in the “resting state” of the receptor. New 
knowledge about specific NR has changed the functional profile of the different regions (see Fig. 12) 
 
NRs have a variable N-terminal modulator region, a well conserved central domain and a 
relatively well conserved C-terminal ligand-binding domain. The central domain forms 
structural motifs called zinc fingers (zinc ions bind to cysteine and histidine and thereby 
stabilize polypeptide loops) accounting for DNA binding. Ligand binds to the C-terminal 
region. For some receptors (orphan receptor like nerve growth factor induced clone 
B/NR4A1) the ligand is unknown. Upon translocation to the nucleus NRs bind to 
responsive elements in the promoter regions of target genes. Consensus sequences have 
been published for most nuclear receptors except mineral corticoid receptor (MR, 117). 
With new identification techniques 150 base sequence variants could be identified for 
the Glucocorticoid responsive element (GRE) alone 118). In addition, responsive 
elements are not strictly possessed by one receptor type.  Mineralcorticoid receptor 
(MR) or the progesterone receptor can for example bind to the GRE. Responsive 
elements can induce and reduce expression of a target gene. The contrary to the 
“positive” GRE is the “negative” mouse mammary tumor virus hormone responsive 
element (MMTV-HRE), which reduces expression of target genes. 
An evolutionary-based nomenclature of the NR superfamily was published in 1999 
(119). It consists of 6 evolutionary closely related subgroups (NR1-6). NRs have been 
found in most metazoans (multicellular animals with differentiated tissues) and gene 
sequences and protein structures are markedly conserved.  
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1.6.1 Glucocorticoid receptor (NR3C1) and its ligands 
 
The discovery of GC and the GR started with the study of hormones from organ extracts 
(for review see 120). Later on the connection between stress and amelioration in 
autoimmune disease or allergy was recognized and lead to the first clinical application 
of Cort in 1948 (24). After this initial trial the pharmaceutical industry developed many 
different substances related to the original steroid hormone purified from organ extract 
(121). Prominent members of the first generation of GCs are prednisolone and Dex. With 
treatment trials a range of GC side effects on different organs emerged (see also 1.3), 
among these changes in glucose and insulin level, bone, fluid and electrolyte balance and 
CNS symptoms like depression.  
Radioactively labelled GCs could now also be used to define binding sites in cells. One of 
the earliest reports describes nuclear binding sites in rat thymus cells (122). GR is found 
in most cells types of the body. The GR was first cloned in 1985 and found to exist in two 
alternatively spliced transcripts: hGRα and hGRβ (Fig. 12, 115). Whereas the hGRα acts 
as a classical ligand operated nuclear receptor, hGRβ does not interact with GCs or bind 
to GRE. It has a varied expression in different mammalians, tissues, and cell types in the 
same tissue. Cotransfection with hGRα revealed a dominant negative effect on GR action, 
thereby connecting the expression level of hGRβ to steroid resistance (123).  
 
  
Figure 12. Structure of the hGR according to Zhou et al. 2005 (123). 
The N-terminus represents the constitutive transcriptional activation function 1 (AF1), while the C-
terminus encodes the ligand-binding domain (LBD) and ligand-dependent activation function 2 (AF2). The 
highly conserved DNA-binding domain (DBD) is located in the central region of the protein. In addition, 
the domains involved in nuclear localization, receptor dimerization, and cofactor binding are mainly 
localized to the C-terminal ligand-binding motif. H hinge region. 
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GR forms an oligomer with heat shock protein 90 (hsp90), hsp70, p23, and hsp90-
binding tetratricopeptide repeat protein in its resting state in the cytoplasm. Upon 
binding of ligand, hsp 70 dissociates and GR initiates transport to the nucleus through a 
rapid hsp90 dependent and a slower hsp90 independent mechanism (the latter thought 
to be mainly diffusion, 124). Hsp90 stays in the complex with GR on the way from the 
cytoplasm to the nucleus and in the nucleus itself. It is suggested that it might even be 
important for relocation of GR to the cytoplasm (124). Hsp90 also facilitates binding to 
the microtubules and is especially important for long distance transport in neurites of 
neurons (125). Other molecules like importins also play a role in nuclear import and 
export of the GR (for review see 125).  
A steroid ligand may bind both to GR and MR, but with different affinity (Fig. 13). The 
mineralcorticoid aldosterone binds with high affinity to MR and with lower affinity to 
GR (Fig. 10, 126).  
 
 
Figure 13. Affinity of different steroid ligands to MR and GR respectively according to Rupprecht et al., 
1993 (126) 
Binding affinity (Ki values determined from the displacement curves) vs. functional sensitivity (ED50) in 
the co-transfection assay for human mineralocorticoid (left panel) and human glucocorticoid receptor 
(right panel). In order to estimate ED50 values SK-N- MC cells were cotransfected with MTV-LUC 
(mammary tumor virus luciferase response element) and either human mineralocorticoid receptor or 
human glucocorticoid receptor. The induction of the MTV-promoter was calculated from the relative light 
units measured in the individual cell extracts with or without ligand treatment. The baseline activity of the 
MTV promoter without addition of hormone, equivalent to approximately 2000 RLU, was set at 1. On the 
resulting dose response curves the functional sensivity (ED50) was estimated.  
 
The GR ligand’s affinity and ability to affect gene transcription correlates with its 
“relative steroid potency” (127), which is measured by effects on the HPA axis, glycogen 
GRMR 
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deposition, and anti-inflammatory and eosinopenic effects. Recently, evidence has 
emerged that suggests that some aspects of GC effect like induction of cell death might 
not correlate with “relative steroid potency” (paper 1, 128), suggesting alternative 
steroid pathways or effects on different receptors.  
Receptor agonists and antagonists provide a useful tool for the study of hormone-
induced effects. The development of the selective GR agonist RU28362 and the mineral 
corticoid receptor antagonist RU28318 made it possible to dissect the effects of the GR 
and MR in different tissues. The competitive GR antagonist Mifepristone or RU38486 
was developed as an abortion drug. It has strong anti-glucocorticoid and anti-
progesterone effects coinciding with a high affinity to the GR and PR (129). Notably, in 
some species like chicken RU486 does not react with the PR but only with the GR (130).  
 
1.6.1.1 GR and its ligands in the immature and mature CNS 
 
Although GC administration is mainly targeting GRs outside the CNS, side effects on the 
brain have been noted early on (24). 
Studies in the rat brain show that GR expression is distributed over the whole brain with 
high density in the olfactory cortex, hippocampal formation, amygdala, hypothalamus 
and cerebellum (131). A study in newborn mice found that GR is expressed in highest 
amount in the neonatal cerebellum (132). In contrast, MR is not expressed in detectable 
levels in cerebellum, but has its highest expression in the hippocampus. Notably, the MR 
in the CNS does not show mineral corticoid selectivity and will bind e.g. Cort with higher 
affinity than the GR (133). Thereby Cort, the endogen steroid in birds and rodents, or 
HC, the endogen steroid in dogs and primates, can occupy all of the MR in the brain at 
low basal levels. In order to exert GR mediated effects in the brain levels of naturally 
occurring, steroid have to be high e.g. with stress. 
The access of glucocorticoids to the brain is dependent on several factors, among these 
binding to the corticosteroid-binding globulin (CBG) in blood, local metabolic 
conversion of steroids influenced by 11β-hydroxysteroid dehydrogenases, and the 
blood-brain barrier (BBB).  
About 95 % of circulating Cort and 75 % of HC are bound to CBG (HC binds in ca 20% to 
serum albumin) thus only leaving 5% as biologically active. Dex has a low affinity for 
CBG and is mostly bound to albumin. Plasma protein binding for Dex has been reported 
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to be 68-75% (134). Stress downregulates CBG thereby increasing the availability of free 
Cort and HC (135).  
Next, steroids must cross the BBB in order to exert their effect in the brain tissue. Dex 
and other high potency steroids are more lipid soluble agents than naturally occurring 
steroids, and thus could cross the BBB more readily. In addition the BBB function may 
be reduced in premature infants (136). On the other hand the ABC transporter protein 
Mdr1a expressed in endothelial cells of the BBB can specifically prevent synthetic 
steroids from passing the barrier (137). But subsequent studies in pregnant guinea pigs 
showed that Dex, given to mothers, dose dependently reduces CRH mRNA in the fetus, 
thus indicating that synthetic GCs indeed pass the BBB in appreciable amounts in 
immature organisms (138) probably most likely because of the diminished barrier 
function in premature infants.  
When GCs finally have crossed the BBB, there are other factors that influence GC effect. 
Among these the enzyme 11-beta-hydroxysteroid-dehydrogenase type 2 (11β-HSD2) 
has a role as inactivator of Cort. It is expressed in the developing CNS, including 
cerebellar granule neurons (139) and blocks endogenous GC effects.  
 
1.6.1.2 Non-genomic actions of GR 
 
Early reports of rapid or non-classical actions of steroids described instant anesthetic 
effects of injected progesterone in rats (140) and rapid action of aldosterone (141). 
The common denominator was the short time of action that was not compatible with the 
classic genomic action of steroids. In recent years rapid signalling for almost all steroid 
hormones has been discovered (142). In 2003 the Mannheim classification categorized 
non-genomic steroid actions into two main types: direct and indirect, meaning that 
steroid hormone acts alone or with a co-agonist, respectively  (143). For further 
specification see fig. 14. The non-classical steroid action can principally be signalled 
either by the classical steroid nuclear receptor or by a non-classical e.g. membrane 
bound receptor.  
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Figure 14. Mannheim classification of non-genomic steroid action according to Losel et al., 2003 (143).  
 
Also for all other steroid ligands the existence of membrane-bound classical or non-
classical receptors has been proposed (for review see 143).  
Examples of rapid non-genomic action in the CNS involved serotonergic responses in the 
limbic system of lizards 20min after injection of Cort (144), transient increase of 
aspartate and glutamate levels in the CA1 area of the hippocampus 15 min after 
injection of Cort (145) and increase of Na+ -dependent uptake of glutamate in rat 
cerebral cortex synaptosomes 15 min after injection of Dex (146).  Behavioural changes 
as a possible consequence of biochemical changes in the CNS could also be 
demonstrated. Suppression of courtship behaviour by stress could be mimicked by 
injection of Cort in the amphibian Taricha granulosa already 8 minutes after injection 
(147).  
Membrane-bound GR may have a role in programmed cell death. Its involvement has 
been demonstrated for the apoptosis of human lymphocytes in the CCRF-CEM cell line 
(148). Since Dex killed cerebellar granule neurons in rats rapidly and the NMDA 
receptor antagonist MK801 blocked this action, a cross talk between the NMDA receptor 
and an either membrane-bound or cytosolic GR has been proposed (for more detailed 
discussion of GR/NMDA interaction see paper 1 and 2).   
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1.6.2 NR4 group  
 
The first member of this group, nerve growth factor induced clone B (NGFI-B), was 
described in 1988 (149). All members (NGFI-B or NR4A1, Nurr1 or NR4A2, NOR1 or 
NR4A3) are so-called “orphan” receptors meaning that they have no known ligand. A 
hydrophobic cleft as ligand binding site for steroid hormones has not been found in 
these receptors. NGFI-B and the other members of the NR4 group were eventually found 
to be immediate early genes, which are activated rapidly, transiently and independently 
of protein synthesis by multiple stimuli including phorbol esters, growth factors, calcium 
ionophores and membrane depolarization (150, 151).  
The receptors can bind to a specific response element called NGFI-B response element 
(NBRE) and a palindromic version of NBRE called NurRE. Homodimers bind 
preferentially to NuRE. Heterodimers, which e.g. contain retinoid X receptor, bind 
preferentially to several sequences of NBRE (152, 153, 154, 155, 156). The target genes 
of the NR4 group are largely unknown (157) but the NR4 group plays a role in the 
development of dopaminergic neurons in the midbrain and in regulation of the HPA axis 
of steroid synthesis (see 1.6.2.1) as well as apoptosis.  
The members of the NR4A family have as yet not been cloned in chicken, but 
homologues of NGFI-B are found in several species, including rat (NGFI-B), mouse 
(nur77), and human (TR3), as well as non-mammalian model organisms such as Xenopus 
laevis (158), and the zebra fish Danio rerio. NR4A2 and NR4A3 homologues are also 
found in both zebra fish and Xenopus.  
 
1.6.2.1 NR4 in the CNS 
 
Both NGFI-B and Nurr 1 are expressed in mouse brain with variations depending on the 
developmental stage. Nurr1 could be detected early on in the embryo while NGFI-B first 
was detected postnatally. Both are also expressed in cerebellum (159). NOR1 was 
detected only in low levels in the brain. No obvious differences of development were 
shown in knockout mouse models of NGFI-B (160) whereas knockout models for Nurr1 
died 12 hours after birth. Analysis revealed that Nurr1 is essential for the survival of 
dopaminergic neurons in the midbrain that are lost in Parkinson disease (161). 
Another role for Nurr 1 and NGFI-B emerged from study of the regulation of the HPA 
axis (see 1.1.3) of steroid synthesis (162). CRH, produced in the paraventricular nucleus 
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of the hypothalamus, induces increase of POMC, a precursor of ACTH in the anterior 
pituitary gland. ACTH in turn increases production of steroid hormones in the adrenal 
gland. Stress induces Nurr 1 and NGFI-B expression in the paraventricular nucleus (CRH 
production) and in the anterior pituitary. Nurr 1 could be shown to enhance 
transcription of CRH in the hypothalamus and ACTH in the anterior pituitary gland. In 
contrast GCs decrease transcription through a negative GRE in the promoter regions of 
CRH and ACTH. Thus Nurr1 has an upregulating effect on steroid hormones. The 
evidence for GR and NR4A group crosstalk is discussed in 5.2.2. 
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2. Aims of the thesis 
 
The aims of the thesis have been to study the influence of glucocortioid hormones on the 
immature central nervous system. 
Subgoals:  
- To establish the chicken embryo cerebellum as a simple model system and chicken 
embryonic cerebellar neuron culture for the evaluation of hormonal effects on immature 
neurons. 
- To investigate the effect of GCs on granule cell proliferation, cell death and 
differentiation in chicken embryo cerebellum and in cerebellar neuron culture. 
- To establish a new method for gene transfection of chicken cerebellar granule neuron 
(CCGN) cultures for the study of GR regulation. 
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3. Methods 
3.1. Chicken embryo cerebellum model 
This thesis presents the chicken embryo cerebellum as a model system to test 
neurotoxic effects of drug exposure in early life. The chicken embryo is a classical model 
organism for developmental and neurobiological studies (163). Lately the whole chicken 
genome has been sequenced and a 75 % similarity to the human genome was found. 
Differences include the lack of gene families related to egg laying in the human genome 
(163). The chicken embryo represents a practical and low cost animal model, which 
reproduces quickly and does not require animal facilities. The maturation of the chick 
embryo is only dependent on the correct temperature and humidity during incubation. 
The yolk sac contains initially the maternally derived steroid hormone Cort, though not 
HC. Cort, the main GC in birds, had a concentration of 1,8 ng/ml (5,2 μM/l) on ED16 in 
the embryo and increased to 2,3ng/ml (6,6 μM/l) before hatching (164). Thus basal 
levels of endogenous Cort are low, and effects observed with GC treatment would mainly 
be a consequence of administered GCs. The chick GR has been cloned and has a 
homology of 73% with the human GR (165). 
Administration of GCs through the eggshell resulted in changes of chicken 
neuroendocrinological tissue in earlier studies (166). Jochemsen et al. (167) showed 
that BrdU could be detected in various chicken organs 24 hours after injection, though 
not in all embryos (167).   
The histological architecture of the cerebellum is markedly conserved in all vertebrae. 
The adult vertebrate cerebellum has three layers (66) comprising the ML, the PL and the 
IGL. During development the EGL appears as a temporary structure (see section 1.5), 
which in man exists up to 2 years after birth and in birds until about 9-10 days after 
hatching. Main cell types are easily identifiable in the different layers. 
Based on histological criteria like EGL thickness developmental stages of the animal 
model cerebellum can be compared to stages in the human cerebellum (55). The chicken 
cerebellum on E17 (paper 2 and 4) has a relatively thick EGL, at least a bilayer of 
Purkinje cells and no apparent glial fibrillary acid protein expression, thus resembling 
the human cerebellar cortex in late 2nd to early 3rd trimester, i.e. about 24 to 32 
gestational weeks (168, 55).  
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3.2 Chicken cerebellar granule neuron (CCGN) culture 
 
Rat cerebellar granule neuron cultures have been extensively used for studies of 
excitotoxicity and apoptosis (150, 89), but our group first established chicken cerebellar 
granule neuron cultures in 2006 (paper 1). The combination of the in vivo model with 
cell culture offers possibilities for the confirmation of results and the in depth study of 
mechanisms by transferring observed phenomena from the in vivo model to the more 
easily manipulated cell culture. Thus, GC effects on apoptosis, proliferation and 
differentiation of granule neurons in GC treated cerebella could be confirmed in cell 
culture (paper 2 and 4). Purified granule cell cultures can be treated with agonists and 
antagonists of intracellular signalling pathways (paper 1,2 and 4). 
Chicken cerebellar granule cell cultures (CCGNs) are also suitable for transfection 
techniques. CCGNs can be transfected with a plasmid encoding the protein of interest 
and by different transfection techniques suitable for biochemical and microscopic 
studies (paper 3).  
The cerebellar neuron culture is an artificial cell system. Neurons do not connect 
properly with their target cells and axonal-dendritic orientation is disturbed. CCGNs 
seem mainly to derive from the EGL (169) thus representing the immature granule 
precursor population. On day 3 though, neurons show expression of glutamate receptors 
(paper1) and NeuN (paper 4) indicating a differentiation process. A low dose of the 
cytostatic agent AraC was used to prevent overgrowth of astrocytes. Under these 
conditions a purity of 80% CCGNs was achieved in culture.  
The use of chicken serum (10%), which is not analyzed in all its components, implies 
that interaction with unknown growth and survival factors cannot be ruled out, and may 
influence reproducibility of results of experiments in culture.  
When compared to cultured cerebellar granule neurons from young rats, a well-known 
model for the study of excitotoxicity (170), CCGNs had the advantage that they could be 
grown in 5mM K+. Thus, CCGNs could be cultured under more physiological conditions 
than rat neurons, which demand depolarizing conditions (25mM K+, 171). It could also 
be shown that CCGNs mature earlier in culture than rat neurons since excitotoxicity was 
induced earlier in chicken culture (3 days in vitro, DIV) compared to rat (7 DIV, paper 1).  
 
 
 
 44 
 
3.3 Methods for the detection of apoptosis  
 
Cerebellar slices were stained with hematoxylin and eosin (HE) for histological 
identification and quantification of apoptotic cells. The cytoplasm of apoptotic cells 
becomes eosinophilic and cells and nuclei condense, resulting in a distinct cell 
morphology (paper 2). These morphological changes still represent the gold standard 
for the detection of apoptosis. Caspase-3 expression, frequently used for the detection of 
apoptotic death, showed a similar dose-dependent GC effect. Caspase-3 expression gives 
an indication of apoptotic death, but apoptosis can also be a caspase-independent 
process and caspases are not only activated in other processes than apoptosis (172). 
Thus, in addition to caspase-3 immunohistochemistry other methods of apoptosis 
detection have to be used.  
For the detection of apoptotic death in CCGN culture (paper 2) a combination of four 
different techniques was used. Firstly, the trypan blue exclusion assay is based on cell 
membrane impermeability for trypan blue in living cells. The trypan blue assay in 
combination with phase contrast allows for identification of the cell type of the dead cell. 
But the assay cannot distinguish necrotic and apoptotic cells. Secondly, caspase-3 
immunohistochemistry was used for determining apoptosis. The amount of caspase-3 
positive cells in culture was lower than the amount of trypan blue including cells, 
because the trypan blue assay includes all dead cells independent of cell death 
mechanism. Decrease of nuclear diameter represents another typical feature of 
apoptosis (173), which was applied to rule out false-positive caspase-activation 172. As 
a fourth method, caspase-3-dependent cell death was confirmed by using caspase-3-
inhibitor to block GC induced cell death on cultured neurons.  
Quantification of cell death can be problematic in model systems since apoptotic cells 
are removed rapidly from the system by phagocytosis (75, 174). In the chicken 
cerebellum peak apoptotic cell death is reached around E16 (unpublished results). Thus, 
a high turnover of immature neurons occurs in a relative short time span. This allows 
apoptotic cells in the chicken cerebellum to be quantified both at basal rates and 
increased rates after drug exposure (paper 2).  
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3.4 Methods for the detection of proliferation and differentiation 
 
BrdU incorporation is a common method to measure cell proliferation in vivo (paper 4). 
The antibody is directed against BrdU in the nucleus and dividing cells incorporating 
BrdU are stained. BrdU can be detected in cells several days after cell division (169). 
BrdU was injected 3 hours before sacrifice in this study (paper 4). Thereby most likely 
cells in S-phase were marked, as the S-phase of the cell cycle in neurons lasts about 3 
hours (175). In cultures proliferating cell nuclear antigen (PCNA) was used, which is 
expressed by proliferating cells in the S-phase (paper 4).  
NeuN and microtubule-associated protein 2 (Map2) were used as differentiation 
markers of postmitotic neurons (paper 4, 176, 177,178).  
 
3.5 Transfection of CCGN 
 
The transfection of neurons has generally proven to be difficult. While transfection using 
liposomes is a well-known transfection technique for adherent cells, electroporation has 
traditionally been used for transfection of cells in suspension. The development of 
instruments such as the Cellaxess® CX1 system also made the latter method applicable 
to adherent cells (paper 3). In paper 3 two transfection methods were compared and 
optimized for use in CCGN. The relatively high amount of DNA used for transfection 
represents one of the disadvantages of the electroporation method. Also, this method is 
based on a strong electrical current that leads to a disruption of the cell membrane, 
which in turn allow plasmids to enter the cell (179). It can be assumed that neurons in 
the whole culture dish will be exposed to a certain degree of electrical shock and this can 
have the potential of changing cell culture properties. Such electrical impulses as given 
during the electroporation procedure have been shown to profoundly alter the genetic 
profile, especially the expression of growth factors in neuronal tissues (180, 181, 182) 
and consequently also biological processes such as apoptosis and proliferation can be 
affected (182). Further investigations into these side effects of electroporation on CCGN 
culture are required. In our studies the liposome method was most suitable for 
biochemical studies and was used for measuring GR mediated gene transcription by Dex 
and HC (paper 2) and the interaction between GR and NGFI-B (paper 3). On the other 
hand, the electroporation method was used for protein localization studies (paper 3). 
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4. Summary of papers 
 
Paper 1 
 
This paper describes how CCGNs are prepared and how such cultures can be use as a 
model for detecting neuronal damage by diverse agents. An 80% enriched neuronal 
culture was achieved by adapting the established method of preparing rat cerebellar 
neuronal culture and by using chicken serum instead of fetal bovine serum in the culture 
medium. Chicken cultures developed more rapidly than rat neuron cultures as indicated 
by earlier neurotoxic reaction to glutamate. Unexpectedly, CCGNs could also be grown in 
medium containing 5 mM K+  (physiological concentration) without significant change in 
survival in contrast to rat cerebellar neurons, which demanded 25 mM K+ in the culture 
medium. When assessed for cell death mechanisms CCGN showed similar production of 
reactive oxygen species (ROS) measured by dihydroethidium oxidation, similar level of 
caspase-3 activation measured by caspase-3 assay and immunofluorescent staining of 
expressed caspase-3 protein as rat cultures. 
The CCGN culture therefore provides a useful, low-cost and reproducible method for 
studying neurotoxic mechanisms and holds certain advantages over rat cultures such as 
more physiological cell culture conditions.  
Paper 2 
 
The effects of the high potency steroid Dex and the low potency steroid HC on cell 
survival were evaluated in chicken embryo cerebellum and CCGN culture. Dex and HC 
induced granule cell death in the IGL of the chicken cerebellar cortex and in culture in a 
dose dependent manner. The mode of GC induced cell death was shown to be apoptosis. 
Cells showed typical apoptotic morphology and activation of caspase-3 in chicken 
embryo and CCGN culture. Caspase-3 inhibitor treatment of cerebellar cell cultures 
before GC treatment abolished cell death. Interestingly, cell death induced by Dex and 
HC could be blocked by pretreatment with mineralcorticoid antagonist RU 28318 and 
NMDA receptor antagonist MK801, indicating a possible crosstalk between a membrane-
bound GR and NMDA receptors. Maximum effect on gene transcription for Dex and HC 
was evaluated by transfection of cerebellar neuron culture with a GRE3-Luc reporter 
gene. Dex and HC showed high transcription activity at 0,01nM and at 10nM, 
respectively. Thus, HC concentration needed to induce transcription of target genes was 
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much closer to the dosage causing neurotoxic effects on neurons (1μM) giving HC a less 
favourable treatment profile in vitro when assessing apoptosis.  
 
Paper 3 
 
Two different methods were optimized for transfection of CCGNs. The electroporation 
method using the Cellaxess® system yielded transfected neurons in a local well-defined 
region of the culture dish thus facilitating microscopic studies of tagged target proteins. 
The liposome based method using Metafectene® Pro generated transfected cells evenly 
distributed over the whole culture dish and was therefore more suited for biochemical 
studies. The liposome method was subsequently used to study the interaction of GR with 
NGFI-B. CCGNs were transfected with the reporter gene NBRE8-luc and then treated 
with forskolin and PMA. Relative luciferase activity increased indicating the induction of 
the endogenous NR (nuclear receptor) 4A family in CCGNs. As forskolin and PMA 
unselectively activate a range of other factors, NGFI-B was chosen to be overexpressed 
in CCGNs. Cotransfection with GR reporter gene GRE3-luc revealed that NGFI-B in its 
wild type significantly downregulated ligand (Dex) induced reporter gene activation. A 
C-terminal truncated version of NGFI-B downregulated ligand (Dex) induced reporter 
gene activation non-significantly and much less than wild type NGFI-B, indicating that 
parts of the C-terminal of NGFI-B are involved in crosstalk with the GR.  
 
Paper 4  
 
This paper addressed GC effects on both proliferation and differentiation in chicken 
embryo cerebellum and cell culture. Dex and HC significantly reduced the number of 
proliferating neurons in a dose dependent manner in the IGL of the chicken cerebellum. 
Decreased proliferation appeared to involve the GR, as GR antagonist RU 38486 could 
antagonize this reduction. Dex and HC increased the number of NeuN positive cells in 
the IGL and expression of Map2 in whole cerebellum homogenated lysate. Apart from 
inducing cell death the antimetabolite AraC is also known to arrest cells in G1-phase. 
AraC significantly increased the number of NeuN positive neurons in culture similar to 
Dex thereby indicating that arrest of cells in G1 phase may be sufficient to influence 
differentiation.  
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5. General discussion  
 
5.1 GC effect on apoptosis, proliferation and differentiation in the immature 
cerebellum 
  
Our observation of GC induced apoptosis in the chicken embryo cerebellum and in CCGN 
(paper 2) is in accordance with studies in other species (99), and similar results have 
also been obtained in other brain regions (51, 183, 184). We compared HC to Dex and 
found it to be equally neurotoxic than Dex (paper 2). Other studies have used Dex (51, 
183, 184) but not HC.  In the clinical situation though, Dex seems to be more neurotoxic 
when used for prophylaxis of BPD compared to HC (see 5.4). Different factors might 
account for this difference. Since Dex is more lipophilic than HC Dex may more easily 
cross cell membranes. The ABC transporter protein Mdr1a expressed in the cells of the 
BBB prevents synthetic steroids from passing the barrier (133). But preterm babies are 
known to have a reduced function of the BBB. As a result, Dex might be more neurotoxic 
in humans, although HC shows equal neurotoxicity in our in vivo model. Alternatively, 
other GC effects may be more important, such as effects on proliferation and 
differentiation.   
It has been discussed if MR could signal GC action. Although this might be the case in the 
hippocampus region, MR has not been detected in the fetal cerebellum (185, 186). The 
protective effect of MR antagonist RU28318 may be due to its antagonistic effect on the 
GR (paper 2, 187).  
GCs inhibited neuronal proliferation in vivo in accordance with other studies in the 
cerebellum (paper 4, 54, 99, and other brain regions 188, 189, 190). We found that Dex, 
compared to HC, leads to inhibitory effects on proliferation at lower concentrations, 
which represent the therapeutic range in the clinical situation (paper 4). In CCGN Dex 
(but not HC) showed a significant antiproliferative effect. Other studies have either used 
Dex (189, 190, corticosterone (188) or both in combination (99), or HC in high dosage 
(10mg/kg, 54). If proliferation is inhibited, the final number of functioning neurons in 
the cerebellum will necessarily be reduced. If the reduction is considerable, it will 
manifest itself as smaller cerebellar cortex volumes and secondarily reduced white 
matter volumes. This has been shown for Dex treatment in preterm infants (191) but 
not for HC (192).  
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Dex was shown to have a stronger in vivo and in vitro effect on granule cell proliferation 
than HC (paper 2) whereas the effect on apoptosis was more similar occurring at high 
doses for the two drugs (paper 4). There might, however, also be a direct connection 
between proliferation and apoptosis. It was shown that low dose Dex induced apoptotic 
death of premitotic neurons in the EGL (55). This points to an indirect effect of low dose 
Dex on proliferation rates in the IGL via induction of apoptosis in the EGL.   
In conclusion Dex has significant effects on proliferation and apoptosis in vivo and in 
vitro, whereas HC has significant effects on apoptosis in vivo and in vitro but only a 
moderate effect on proliferation in vivo. This evidence might be reflected in clinical 
results of increased major neurological impairment with Dex treatment but not with HC 
treatment (40).  
We observed increased neuronal differentiation after GC treatment in chicken 
cerebellum and neuronal cell culture (paper 4). Few other publications have studied this 
effect. In mice pups treated with Dex (99) a higher expression of the differentiation 
marker Zic1 was found in whole cell lysates of Dex treated animals compared to 
controls. In contrast, in other brain regions such as adult rat hippocampus (190) and 
newborn primate hippocampus (63) GCs did not increase differentiation. Arrest of cells 
in the G1 phase of the cell cycle as a result of GC treatment (54) may represent the signal 
for neuronal differentiation (paper 4). Thus, increased neuronal differentiation may be a 
consequence of reduced proliferation caused by GC treatment. 
 
5.3 Mechanisms of GC action in CCGN 
5.3.1 Classical versus non-classical GC action 
 
Principally GC action can be classified in classical and non-classical (see chapter 1.7.1.2). 
The classical steroid action involves the cytoplasmatic receptor and transcription of 
target genes. Non-classical actions involve second messengers in their signaling 
pathways and can either be executed via the classical steroid receptor or a putative 
membrane-associated GR. The membrane binding form of GR is characterized by high 
affinity for Cort and HC, and low affinity for aldosterone, Dex and RU 38486, whereas RU 
38486 has high affinity to the cytoplasmatic GR receptor followed by Dex, Cort and 
aldosterone (193). In paper 2 the apoptotic effect of Dex and HC seem to involve a non-
genomic steroid action, supported by the fact that a comparatively high GC dose was 
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needed to result in significant apoptotic effects in vivo and in vitro. The effect was rapid 
as shown in another study in rat (89). Dex-induced cell death could be blocked by 
MK801, a NMDA antagonist, thereby indicating a cross talk between the NMDA receptor 
and a membrane bound GR (paper 2, 89). Possible crosstalk between the GR and the 
NMDA receptor has also been suggested in other studies (194, 195).  
A relatively low dose of Dex compared to HC significantly reduced proliferation and 
induced differentiation in the chicken cerebellum (0,1mg and 5 mg/kg egg respectively, 
paper 4). This reflects the difference in relative steroid potency between Dex and HC. 
Also, the antiproliferative effect of GCs could significantly be blocked by GC antagonist 
RU 38486 (paper 4). RU 38486 has a high affinity to the cytoplasmatic form of the GR. 
Together this evidence argues for a classical steroid effect on proliferation and 
differentiation. Notably, RU 38486 reacts in chicken only with GR and not with PR (130).  
 
5.3.2 Interaction of GR with the nuclear receptor group NR4 in neurons 
 
Early reports about possible interactions between GR and the NR4A group came from 
studies in adult rat hippocampus (196). Here it could be shown that GR mRNA was 
increased and NGFI-B mRNA reduced by placing the animals in an enriched environment 
and measured by in situ hybridization. Philips et al. (197) demonstrated the 
downregulation of the CRH induced transcription of NGFI-B mRNA in a mouse pituitary 
epithelial-like tumor cell line (AtT-20). Reduced transcription of CRH as a result of GC 
interaction with a negative GRE in the CRH promoter (198) could account for 
consecutively reduced transcription of NGFI-B. Furthermore GR-induced repression of 
POMC transcription happened at the NuRE in the promoter region of POMC, but not in a 
binding fashion to the response element but rather a protein-protein interaction 
between GR and NGFI-B and/or other cofactors. NuRE is a palindromic NBRE3 sequence, 
which binds preferably dimers with at least one molecule of NGFI-B (199). Interaction 
between NGFI-B and GR was shown in cells with both proteins overexpressed. In our 
study co-transfected chicken cerebellar neurons with overexpressed wild type NGFI-B 
and NBRE8luc showed no downregulation of NGFI-B-induced gene transcription upon 
treatment with Dex, which activates the endogenous GR (paper 4). The construction of 
the artificial response element with 8 copies of the response sequence might make a 
protein-protein interaction of endogen GR and NGFI-B at the response element less 
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efficient. Also, overexpression of NGFI-B could give such a strong signal that it cannot be 
overcome by endogenous ligand-activated GR. In addition, protein-protein interaction 
could be hampered by a different co-factor profile in chicken cerebellar neurons.  
Philips et al. (197) and Martens et al. (199) try to define the domain of the GR and NGFI-
B, respectively, which interact when mutually blocking gene transcription. In both the 
GR and NGFI-B the DNA-binding domain (DBD) was hypothesized to be dominant in 
blocking interaction although the deletion of the C-terminus in GR led to ligand-
independent blocking (197). The negative control (deleting the DBD) could not be 
performed because this would compromise the reporter gene assay, as the readout is 
dependent on DBD binding. The C-terminal deleted NGFI-B construct (∆ 352) showed a 
slight reduction in blocking the GR/Dex induced GRE-luc activity in contrast to ∆ 380 
construct which shows full blocking activity. The construct used in paper 3 is a ∆ 369-
597 construct of NGFI-B, which lies between the two constructs used of Philips et al. 
concerning its starting point of C-terminal deletion. There was a tendency that NGFI-Btr 
blocked GRE-luc activity to a lesser degree than wild type NGFI-B (paper 4). These 
results suggest that not only the DBD region of NGFI-B is involved in protein-protein 
interaction with GR or a common cofactor (197) but also parts of the C-terminus itself. 
In difference to studies in non-neuronal cell lines (199, 197) paper 3 shows GR and 
NGFI-B interaction in primary cerebellar neuron cultures thereby confirming the 
relevance of this interaction in the CNS.  
 
5.4 Possible clinical implications 
 
It has been suggested that HC might be a potentially safer GC in prophylactic treatment 
of preterm babies for BPD.  Our results support this hypothesis. When the effects on 
apoptosis and proliferation are taken together, HC had a less neurotoxic effect in our 
model compared with Dex (paper 2 and 4). The evaluation of HC as the drug of choice 
for prevention of BPD, however, has to be based on its effects on BPD and 
neurodevelopmental outcome compared to other treatment alternatives such as Dex.   
A meta-analysis of treatment effects in different randomized clinical studies has 
estimated a risk ratio of 0,97 (test for overall effect p=0,37) indicating that treatment 
with HC does not change BPD outcome (fig. 4A, introduction, 40) whereas Dex reduces 
the risk of BPD significantly (risk ratio 0,73, test for overall effect p=0,00001). 
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Several studies addressed the long-term neurodevelopmental consequences of HC using 
different approaches, such as neurological examination, the WISCII test for IQ, the ABC 
test for motor development and MRI brain scanning for structural changes (200, 201, 
202, 203, 192, 204). Results from these studies could not demonstrate significant 
adverse effects of HC on the developing brain. Thus, HC does not seem to have any large 
negative impact on brain development in premature infants, although the connection 
between pathological findings on the MRI of the brain and functional impairment of the 
cerebellum is not always apparent. It is well known that in some types of progressive 
ataxia syndromes the MRI of the brain is essentially normal (205, 206), although 
patients have signs of cerebellar malfunction like ataxia, dysdiadochokinesia and 
dysarthria. Dyskinetic or ataxic CP has no specific signs on MRI (14). It is likely that the 
loss of neurons has to be extensive before volume loss can be detected by MRI. Thus, if 
HC induces a neuronal cell loss in preterm infants, this might be undectable by current 
MRI technique. Dex-treated children, on the other hand, showed reduced ABC test 
performance and a reduction of cerebral gray matter (191).  
Our chick model and other models suggest dose-dependent effects of HC on cerebellar 
neuronal death and proliferation (paper 2, 54, 53). Since HC has shown little effect on 
prevention of BPD in premature infants and at the same time induces dose-dependent 
neurotoxic effects in animal models, HC may not be the drug of choice for the treatment 
of BPD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 53 
 
6 Future perspectives 
 
The chicken embryo cerebellum including cerebellar neuron culture is a useful model 
for drug-induced CNS effects. Rapid development, independence of host organism, easy 
and cheap manipulation and also the completed sequencing of the whole chicken 
genome suggest that this model system would be well suited for further 
neurotoxicological studies. It has already been implemented in a joint Norwegian safety 
pharmacology research project granted funding by the Research Council of Norway (ISP-
Pharm, Projectno: 195484). The project is aiming at expanding the knowledge and 
reliability of the existing model. Different agents will be tested for their neurotoxic 
potency in the model in vivo and in vitro. 
Which other important research questions should be addressed next?  
Premature birth is often associated with chorioamnionitis and preterm infants have a 
variable degree of RDS and require - especially with extreme premature gestational age - 
artificial ventilation leading, among other factors, to a risk for periodical 
hypooxygenation. Ahlbom et al. (57) have shown that GC treatment renders cells more 
vulnerable to oxidative stress even after considerably long time after exposure in utero. 
It would be therefore of interest to test the effect of GCs together with other conditions 
such as hypoxia and inflammation.  
Effects of MK801, a selective NMDA antagonist on GC action has been described in paper 
4. It would be interesting to show a possible cross talk between the GR and the NMDA 
receptor by direct protein technique and to further characterize this interaction. This 
also applies for the crosstalk between GR and other members of the nuclear family, such 
as Nurr-1, the predominant member of the NR4 group in the brain.  
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7 Conclusions 
 
- The chicken embryo cerebellum represents a practical model organ for the study 
of toxic effects on different aspect of neuronal development. The chicken embryo 
model is easy to manipulate and generates low costs.  
- The chicken cerebellar neuron culture is a highly enriched primary neuronal 
culture that can be grown under physiological conditions and can be used for 
various molecular study techniques such as immunochemistry and transfection. 
- GCs induce apoptotic death and differentiation and reduce proliferation in 
granule neurons of the chicken embryo cerebellum and granule neuron culture. 
Dex was more potent than HC with regard to effect on proliferation and 
differentiation, but the two agents showed equal magnitude of effect on 
apoptosis. 
- Apoptotic death by GC treatment seems to be initiated through a non-classical 
steroid action, possibly involving membrane bound GR and cross talk with the 
NMDA receptor, whereas the GC effect on proliferation appears to be mediated 
via a classical steroid action. 
- Endogenous ligand activated GR action on target genes can be blocked by the 
orphan nuclear receptor NGFI-B in chicken cerebellar granule neuron culture.  
- Since HC has no documented clinical effect on the development of BPD in relevant 
meta-analyses, but dose-dependent effects on neuronal apoptosis and 
proliferation in animal models including immature chicken cerebellum, HC may 
not be the best option for prevention of BPD in preterm infants. 
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Abstract 
 
Glucocorticoid (GC) treatment in premature infants may have detrimental effects on the 
immature brain. Here we show that GCs dexamethasone (Dex) and hydrocortisone (HC) 
reduce proliferation and induce differentiation of chicken embryo cerebellar neurons in vivo 
and in vitro. Granule neurons incorporating bromodeoxyruridine were reduced in the 
internal granular layer (IGL) after 24-h exposure to both substances on embryonic day 17, 
with Dex about 100-fold more potent than HC. The effects were blocked by GR antagonist RU 
38486. Both GCs also increased the expression of neuronal differentiation markers 
microtubule-associated protein 2 (Map2) and neuronal nuclei protein (NeuN), measured by 
western blotting of whole cerebellar lysates and immunohistochemistry, respectively. 
Treatment of cerebellar granule neuron cultures with both GCs significantly reduced the 
percentage of proliferating-cell nuclear antigen (PCNA) positive neurons and increased 
NeuN positive neurons, with similar dose-response relationship as in vivo. The cytostatic 
agent cytosine arabinoside showed comparable effects both on proliferation and 
differentiation. In conclusion, the effects of Dex and HC on chicken cerebellar granule neuron 
proliferation are GR mediated and reflect their pharmacological potency. In addition, the 
effects on differentiation may be related to a cell cycle block per se, since cytosine 
arabinoside mimicked the effect of the GCs.  
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Abbreviations 
AraC Cytosine arabinoside 
BrdU Bromdeoxyruridine  
CCGN Chicken cerebellar granule neuron  
DAB Diaminobenzidine  
Dex Dexamethasone 
DIV Days in vitro 
EGL External granular layer 
GC Glucocorticoid 
HC  Hydrocortisone/Cortisol 
IGL Internal granular layer 
Map2 Microtubule-associated protein 2 
NeuN Neuronal nuclei protein 
PCNA Proliferating cell nuclear antigen 
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Introduction  
 
Antenatal treatment with glucocorticosteroids (GCs) accelerates lung maturation in 
premature infants. GCs are also used in treatment of bronchopulmonal dysplasia and a 
variety of other complications that affect premature infants after birth. In recent years 
evidence has accumulated that postnatal GC treatment of premature infants may cause 
cerebral palsy and more subtle motor deficiencies (1, 2, 3). One of the target organs of GCs 
may be the developing cerebellum, as indicated by studies in several animal models (4, 5, 6).  
Brain development is an intricately complex process involving cell proliferation, 
programmed cell death (apoptosis) and differentiation. We have previously used a chicken 
embryo model to show that a single dose of dexamethasone (Dex) and hydrocortisone (HC) 
injected at embryonic day (E)16 increases apoptosis in cerebellar granule neurons, both in 
vivo and in vitro (6). The effect of Dex and HC was rapid and the agents showed equal 
potency, indicating a non-classical (non-transcription dependent) mechanism of action. Dex-
induced neuronal apoptosis in the external granular layer (EGL) of the cerebellum has also 
been reported in mice (4). Additionally, GCs are known to promote cell death in neurons in 
other parts of the brain (7, 8, 9).  
Cell proliferation and apoptosis are opposing determinants of brain growth, and the 
former is the focus of the present study. Using BrdU labeling we have studied the effect of 
Dex and HC treatment of chicken embryos on cerebellar granule neuron proliferation in the 
IGL, and further extended the investigation to purified cerebellar granule neurons in vitro. A 
significant inhibition of proliferation was demonstrated. Interestingly, this effect was 
coupled to neuronal differentiation, as measured by an increased expression of neuronal 
maturation markers, Map2 and NeuN. This differentiation effect may be caused by a block in 
the G1 phase of the cell cycle, as the antimetabolite and cell cycle inhibitor cytosine 
arabinoside (AraC) gave a similar differentiation response. 
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Material and methods 
 
Chicken embryos 
Eggs (weight 50–60 g) from Gallus gallus from different hatches were obtained from 
Samvirkekylling, Våler, Norway. The eggs were incubated in an incubator (Covatutto 20+20, 
Novital) at 37 °C for 16 days. Dex and HC were injected via openings of about 1 mm into the 
amniotic cavity (avoiding blood vessels by light transillumination) in three different dosages 
24 hours before the embryos were sacrificed. BrdU (80mg/ kg egg) was injected via the 
same opening 3 hours before the embryo was anesthetized and decapitated. In a subset of 
experiments RU38486 (20mg/kg egg) was injected into chicken eggs 3 hours prior to 
injection of Dex and HC. After fixation for 24 h in 4% paraformaldehyde in phosphate 
buffered saline, the brain was removed from the skull and fixed for a further 24 h. Coronal 
sections of the brain were routinely processed and slides stained with hematoxylin eosin.  
 
Chicken granule neuron cultures 
Chicken cerebellar granule neurons (CCGNs) were isolated as previously described 10. 
Briefly, cerebellar tissue was first treated with BSA and trypsin (Sigma Chemical Co., St. 
Louis, MO), and then with DNase (Sigma Chemicals Co.), trypsin-inhibitor, and MgSO4. The 
cell suspension was placed in MgSO4/CaCl2 solution and centrifuged a third time. Then 1.8 × 
106 cells/ml were seeded onto poly-L-lysine-coated dishes and incubated in BME containing 
10% heat inactivated chicken serum at 37 °C and 5% CO2. After 3 days in vitro (DIV) cells 
were incubated with Dex or HC directly into the medium. In a subset of experiments AraC 
(Sigma Aldrich Chemie GmbH, Germany) in a concentration of 10 μM diluted in growth 
medium was added on DIV3. Cells were fixed in paraformaldehyde 4% for 5 min on DIV4. 
 
Reagents 
Pure Dex and HC (Sigma Aldrich Chemie GmbH, Germany) were dissolved in ethanol and 
diluted with 0,9% saline. BrdU (Sigma Aldrich Chemie GmbH, Germany) was diluted in 
saline. All final solutions (including saline control) contained the same amount of ethanol, 
giving a final ethanol concentration in the chicken egg of approximately 0,2μl/g egg. This had 
no significant effect on cerebellar granule cell death and proliferation (results not shown).  
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Detection of cell proliferation and differentiation in chicken cerebellum by morphology and 
immunohistochemistry  
Epitope demasking on slides was performed in a microwave oven for 24 min in target 
retrieval solution (DAKO AS, Denmark). Cerebellar microsections were then stained with the 
primary anti-BrdU antibody 1:1600 (Becton Dickinson, USA) or anti-NeuN 1:250 (Chemicon 
Int. Inc, USA) overnight and then for 2 h with horseradish-peroxidase labeled second layer 
IgG antibody, followed by diaminobenzidine (DAB) reaction according to the producer’s 
manual (EnVision+ System HRP, DAKO AS, Denmark). The appropriate blocking solution for 
endogen peroxidase was used in the staining procedure. Three images were taken from the 
IGL of each chicken embryo cerebellum. Images were then processed by Image J software. 
The ratio BrdU or NeuN positive (brown cell nuclei) versus all cell nuclei (blue nuclei) was 
calculated.  
 
Double staining of BrdU and Map2 
Epitope demasking on slides was performed in a microwave oven for 24 min in target 
retrieval solution (DAKO AS, Denmark). Cerebellar microsections were then incubated first 
with primary anti-BrdU antibody 1:1600 for 1 hour and then for 30 min with horseradish-
peroxidase labeled second layer IgG antibody followed by DAB reaction. Slides were then 
washed with H2O and Tris buffer according to the producer’s manual (EnVisionTM G|2 
Doublestain Rabbit/Mus, DAKO Denmark AS), and incubated with second primary anti-
Map2 antibody (Chemicon Int. Inc., USA) 1:2400 overnight 4ºC with alkaline phosphatase 
labeled secondary antibody for 30 min followed by the Permanent Red chromogen reaction.  
 
Detection of Map2 by Western blot in cerebella 
GC treated chicken were sacrificed and the cerebellum was immediately immersed in ice-
cold TE buffer (Tris 10mM, EDTA 1mM) with proteinase inhibitors (leupeptin 1μg/ml, 
pepstatin 1μg/ml, PMSF 0,3mM) and homogenized with 10-12 strokes with the pestle of a 
glass homogenizer and stored in -70º C. Equal amounts of cell lysates from cerebellum were 
mixed and boiled with 2 x Laemmli buffer reduced with 2-mercaptoethanol and subjected to 
electrophoresis on a 10% polyacrylamide gel. Proteins were transferred onto pure 
nitrocellulose membrane. After protein transfer, the membranes were incubated in TBS-T 
(100 mM Tris-HCl, 100 mM NaCl, and 0.1% Tween 20) with 5% nonfat milk and primary 
Map2 (diluted 1:200) followed by a horseradish peroxidase-linked rabbit anti-mouse 
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antibody (diluted 1:5000). Immunoreactive bands were visualized with Super Signal West 
Femto Maximum Sensivity Substrate detection kit (Thermo Scientific, USA).     
 
Detection of cell proliferation and differentiation in chicken cerebellar cultures by morphology 
and immunofluorescence 
Fixed cell cultures were incubated with blocking serum for 1 hour and then incubated with 
primary anti-PCNA antibody (DAKO Denmark AS) 1:200 or anti-NeuN 1:200 overnight. After 
washing with PBS cell cultures were incubated with secondary Cy3 antibody 1:200 for 1 
hour. After washing with PBS nuclei were counterstained with 4′,6-diamidino-2-
phenylindole (DAPI). Photomicrographs were randomly taken with a Nikon fluorescence 
microscope TE 2000 at 400× magnification from two different places per antigen in two 
culture dishes for each separate experiment. Images were taken with UV filter (excitation 
360– 370 nanometers) for the visualization of DAPI, with green filter (excitation 510–560 
nanometers) for the visualization of PCNA or NeuN, and then as phase contrast. The 
percentage of PCNA or NeuN positive cells relative to all DAPI-positive cells was calculated 
using the NIS Elements software version BR 3.0 (Nikon). Only positive labeled cells, which 
had granule cell shape in phase contrast, were used for percentage calculation.  
 
Statistical analysis 
Group differences were tested either using standard analysis of variance (ANOVA) or 
Kruskal–Wallis tests depending on whether or not the data passed evaluations for Gaussian 
distributions. To account for multiple comparisons, we used Dunnett test when comparing 
treatments to a reference group. All tests are two sided, and results with p<0.05 were 
considered significant. All estimates are presented with standard error of means when 
appropriate. 
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Results 
 
Dex and HC reduce the number of proliferating neurons in cerebellum  
We investigated cell proliferation in the cerebellar IGL using BrdU labeling. Chickens at E16 
were treated with different dosages of Dex and HC (0,01mg, 0,1mg, 1mg or 5mg/kg egg) for 
24 h, and BrdU was added 3 h before sacrifice. The CCGN is the dominating cell type in the 
IGL. Only a few cells stain for the glia markers GFAP and S-100 (unpublished results). 
Moreover, doublestaining with the neuron marker Map2 showed that most BrdU 
incorporating cells also expressed Map2 (Fig 1A).  Both Dex and HC reduced percentage of 
proliferating cells relative to all cells in the IGL in a dose-dependent manner (Fig 1B and C). 
Statistically significant reduction in proliferation occurred at 0,1 mg/kg for Dex and at 5 
mg/kg for HC, consistent with a ~ 100-fold difference in potency. The maximum level of 
reduction of proliferation was the same for HC and Dex, approximately 40%.  
 
GR antagonist RU 38486 blocks the effect of Dex and HC on proliferation  
To investigate if the effect of Dex and HC was mediated by GR, eggs were pretreated with GR 
antagonist RU 38486 (20mg/kg egg) for 3 h before treatment with Dex and HC (5mg/kg 
egg). As shown in Fig 2, inhibition of cell proliferation was blocked.  
 
Dex and HC increase the number of CCGNs expressing differentiation markers NeuN and Map2 
in the embryo cerebellum 
Reduced proliferation is often coupled with differentiation in immature cells, and for this 
reason we examined the expression of two important neuronal markers NeuN and Map2. 
Map2 protein is generally accepted as a marker for dendritic outgrowth and consequently of 
mature neurons (11, (12), whereas NeuN is a postmitotic neuronal marker that localizes to 
the nuclear matrix (13, 14). NeuN expression was investigated by immunohistochemical 
staining of cerebellar slides after Dex and HC treatment. Both Dex and HC increased the 
fraction of NeuN positive cells in the IGL from 50% to 70% (Fig. 3A). Map2 cannot be 
quantified immunohistochemically in sections due to expression primarily in neurites, not 
cell bodies. We therefore used western blotting of total homogenated cerebellar lysates.  
Treatment with Dex significantly increased relative expression of Map2 protein (Fig 3B). HC 
treatment increased mean Map2 expression, but the result was not statistically significant.  
 
Effect of Dex and HC on proliferation and differentiation is mimicked by AraC in cell culture 
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CCGN cultures from chicken cerebellum were treated with Dex and HC. A low dose of Dex 
(0,1μM) was chosen because Dex in high dose (10 μM) induces cell death of 50% of cells in 
culture 6. Low dose Dex induced much lower cell death rates (8,5%). Treatment with Dex 
(0,1 μM) significantly reduced the percentage of proliferating cells, as measured by positivity 
for the proliferation marker PCNA (Fig. 4). The reduction detected with HC (10μM) was less 
and not statistically significant. The effect of Dex was almost as potent as treatment with the 
cytostatic agent AraC, used at 10μM. This concentration of AraC did cell death of about 20% 
(unpublished results).  
Differentiation was examined in vitro by measuring expression of NeuN. Dex (0,1 μM) 
significantly increased the percentage of NeuN positive neurons (Fig. 5 A and B). HC (10μM) 
also increased the mean percentage of positive cells, but the result was not statistically 
significant. AraC treatment showed the same magnitude of effect as Dex.  
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Discussion 
 
We have previously investigated the effect of GCs Dex and HC on apoptosis in chicken 
cerebellar granule neurons, demonstrating induction of apoptosis by both agents in the IGL 
(6). This paper addresses proliferation and differentiation same region and in the same cells 
of the cerebellum. Although we previously reported non-significant effects of GCs on 
proliferation in preliminary experiments, more careful investigation revealed a significant, 
dose-dependent decrease. Thus, injection of a single, pharmacological dose of Dex and HC 
led to up to 40% inhibition of proliferation, as measured by BrdU incorporation in the IGL at 
E17. This effect could be blocked by pretreatment of eggs with the GR antagonist RU 38486, 
and was reproduced in CCGNs in vitro. Dex was about 100-fold more potent than HC, a 
reflection of their respective pharmacological potency.  At E17 the background apoptotic 
rate is 0,2% versus a proliferation (BrdU positive) rate of 13%. Dex increases the apoptosis 
rate to ca 0,6% whereas proliferation rate is reduced to 8%. It is, though, difficult to compare 
these two phenomena quantitively, as apoptotic cells quickly are removed from the tissue 
whereas BrdU positive cells not undergo removal. 
 We chose to focus on the IGL in our in vivo experiments. A large fraction of immature 
granule neurons are located in the EGL, but cells are tightly packed and overlay each other, 
making cell counting difficult. However, the granule neurons in the purified cultures derive 
apparently mainly from the EGL (15), and the fact that observed effects in vivo were similar 
in vitro indicates that EGL neurons respond in the same way as IGL neurons. GC effects on 
EGL granule neurons have previously been investigated by Bohn et al. (16) in 1-week-old 
rats, reporting reduced proliferation after treatment with HC. Recently, Heine et al. 
demonstrated a significant inhibition of proliferation in the EGL after chronic exposure of 
postnatal mice to Dex and HC (5). They also investigated the relationship of GC-induced 
growth inhibition with apoptosis, concluding that the contribution of apoptosis was much 
smaller than proliferation to overall cerebellar growth. In contrast, Noguchi et al. (4) 
reported a marked increase in apoptosis in the EGL of mice from postnatal day 4 – 10 after a 
single injection of Dex. We note that in the chicken embryos E16-17 are the most active in 
terms of spontaneous granule neuron division and apoptosis in the IGL. In our experiments 
we found significant GC effects on both proliferation and apoptosis occurring at this time 
point. This period also corresponds to the end of second/beginning of third trimester in 
human pregnancy, the phase where GCs are given in treatment of premature infants, when 
comparing the histological picture of the cerebellar layers (17).  
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 Dex and HC also stimulated differentiation, measured as relative increase of Map2 
protein expression in cerebellar lysates, and increased fraction of NeuN positive granule 
neurons. Again, Dex was more potent than HC. Total cerebellar lysates include other cell 
types than granule neurons, but the latter is dominant in number and it is reasonable to 
conclude that Map2 increase in granule neurons is significant. Increased fraction of NeuN 
positive cells was demonstrated in vivo and in vitro and was relative to total number of live 
neurons. Concomitant apoptosis in vivo conceivable enriches the NeuN positive fraction of 
cells, and the measured fraction in vivo may therefore be overestimated in our study. 
However, in vitro, cell death is low and still an increase of the NeuN positive fraction from 40 
to 70% was observed. In previous studies the effect of GCs on differentiation markers varies 
depending on cell type and developmental stage. Similar to our study, Heine and Rowitch (5) 
recently demonstrated Dex and HC mediated increase in expression of neuronal 
differentiation marker Zic1 in cerebellar granule neurons of rat pups treated from postnatal 
day 5 to 7, although Zic1 protein has been demonstrated also in precursor cells and not only 
differentiated neurons (18, 19). The effect on differentiation may be region dependent as 
other studies show a reduced expression of Map2 in the hippocampus of young and adult 
rats when treated with GCs (20, 21). In conclusion, immature neurons appear to respond to 
GCs by differentiating. Of note, this is paralleled in the immature lung, where GCs are 
powerful inducers of maturation through surfactant production and several other cellular 
differentiation effects (22).  
 The intracellular mechanisms of GC action are remarkably complex, involving both 
GR mediated transcription, directly through binding to GRE or indirectly through binding to 
diverse transcription factors, as well as non-transcription dependent events. Many studies 
have reported a connection between inhibition of proliferation and altered expression of 
myc, cyclin D, p21 and p27 proteins, leading to a block in the G1 phase of the cell cycle (23, 
24, 25). A coupling of myc and cyclin D to exit from G1 has also been shown in immature 
cortical granule neurons in rat (5). Regarding differentiation, present knowledge is less 
clear. Several non-neuronal differentiation markers have GRE containing promoters, and 
interaction with other signaling pathways such as Wnt-betacatenin has recently been 
demonstrated (26, 27). One important question is how to explain mechanistically the 
apparent link between GC mediated proliferation and differentiation observed in our study 
and others. An interesting finding was that the cytostatic agent AraC mimicked the effect of 
Dex and HC in cell culture on proliferation and differentiation, measured as fraction of cells 
expressing PCNA and NeuN, respectively.  Like GCs, AraC causes a block primarily in the G1 
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phase of the cell cycle 28.  We therefore hypothesize that the differentiation effect of GC in 
immature CCGN may be linked to G1 arrest per se, and may not involve specific GC induced 
genes. Supporting this, there are to date no known GRE in the Map2 and NeuN genes.   
A considerable body of literature addresses the impact of stress on neuronal development 
especially in the hippocampus (29, 30) where GCs have been identified as mediators of 
reduced neuronal proliferation in the dentate gyrus. The present study shows that GCs have 
the same effect on immature granule neurons in the cerebellum, in addition to previously 
reported induction of apoptosis. Both of these processes contribute to a reduced number of 
neurons, and could explain findings of reduced grey matter volume in preterm infants 
treated with Dex for prevention of bronchopulmonal dysplasia (31). Accelerated 
differentiation may also be detrimental to cerebellar function and plasticity because of 
possible reduced neurogenesis and impaired connection of granule neurons especially with 
Purkinje cells. The effects of Dex were significantly more potent than HC, suggesting a more 
harmful clinical effect of the former steroid than the latter, in terms of proliferation and 
differentiation.  
In conclusion, this study has shown that the GCs Dex and HC, given as a single dose, 
inhibit proliferation and increase differentiation of cerebellar granule neurons both in vivo 
and in vitro in the chicken embryo model. The effects of Dex and HC were inhibited by GR 
antagonist, and the magnitude of effects reflected their pharmacological potency, suggesting 
a GR mediated mechanism of action. The differentiation is most likely secondary to the 
antiproliferative effect of GCs. Both decreased proliferation and early maturation of neurons 
may lead to reduced cerebellar volume and structural plasticity in the cerebellum, and 
potentially to the impaired cerebellar function demonstrated in clinical studies. 
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Figure legends 
 
Figure 1. Dex and HC treatments reduce proliferation in a dose-dependent manner in the 
internal granular layer in chicken cerebellum.  
(A) Section shows the IGL and whole cerebellum (inset) of chicken embryo at E17. The 
neuron specific marker Map2 (red staining) is most intensely expressed in the Purkinje cell 
layer, but labels the majority of cells of the internal granular layer. BrdU labeled cells 
(brown) show a scattered distribution in the IGL, and most positive cells also stain with 
Map2 (×400 magnification).  
Chicken embryos at E16 were treated with Dex (B) or HC (C) for 24 h in the given doses. 
BrdU positive cells were counted on three photomicrographs (×400 magnification) per 
chicken cerebellum using Image J software. The mean number of BrdU positive cells per 
internal granular layer on photomicrograph is shown with SEM (n=8 experiments). There 
was a significant dose-dependent effect of Dex (* p < 0,05, ** p < 0,01, *** p < 0,001) and HC 
(*p <0,05) compared to control.  
 
Figure 2. GR antagonist RU 38486 blocks effects of Dex and HC on proliferation. 
Chicken embryos at E16 were treated with Dex (5mg/kg egg) and HC (5mg/kg egg) for 24 h. 
Some embryos were pretreated (3 hours) with RU 38486 (20 mg/kg egg). Cells 
incorporating BrdU were counted on three photomicrographs (×400 magnification) per 
chicken cerebellum using Image J software. The mean number of BrdU positive cells per 
internal granular layer photomicrograph is shown with SEM (n=3 experiments).  
 
Figure 3. Dex or HC treatment induces differentiation markers NeuN and Map2. Chicken 
embryos at E16 were treated with Dex or HC, both 5mg/kg egg, for 24 h. (A) NeuN positive 
cells (brown nuclei) were counted on three photomicrographs (×400 magnification) per 
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chicken cerebellum using Image J software. Representative photomicrographs for each 
treatment are shown in the upper section. The mean number of NeuN positive cells per 
internal granular layer on photomicrograph is shown with SEM (n=4 experiments). * p < 
0,05 compared to control.  
(B) Western blots of whole cell lysates from chicken cerebellum subjected to the indicated 
treatments. Blots were labeled with antibody against the differentiation marker Map2 and 
control marker tubulin. One representative blot is shown at the top, and the mean relative 
optical densities for 9 experiments with SEM are shown at the bottom. * p < 0,05 compared 
to control.  
 
Figure 4. Dex or cytosine arabinoside (AraC) treatment reduces cell proliferation in chicken 
cerebellar neuron culture. 
Chicken granule neurons in culture were stained with antibody against PCNA 1:200 and 
DAPI for visualization of the nucleus. Cultured chicken granule cells were treated with 
ethanol as control, Dex (0,1 μM), HC (10 μM) or AraC (10 μM). Photo images were taken with 
a Nikon fluorescence microscope TE 2000 at 400× magnification from two different places in 
two culture dishes/dose and for each separate experiment. Images were shot in the same 
location, first with UV filter (excitation 360– 370 nanometers) for the visualization of DAPI, 
with green filter (excitation 510–560 nanometers) for the visualization of PCNA and then 
with phase contrast. The percentages of PCNA positive cells were determined by counting all 
positive labeled cells with granule cell shape in phase contrast and dividing them by the total 
number of DAPI-positive nuclei using Nikon software. Means are presented with SEM (n = 
6). * p < 0,05 compared to control. 
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Figure 5. Dex or cytosine arabinoside (AraC) treatment induces cell differentiation in 
chicken cerebellar neuron culture. 
(A) Chicken granule neurons in culture were stained with antibody against NeuN 1:200 and 
DAPI for visualization of the nucleus. DAPI pictures are not shown. Cultured chicken granule 
cells were treated with ethanol as control, Dex (0,1 μM), HC (10 μM) or AraC (10 μM). Photo 
images were taken with a Nikon fluorescence microscope TE 2000 at 400× magnification 
from two different places in two culture dishes/dose and for each separate experiment. 
Images were shot in the same location with green filter (excitation 510–560 nanometers) for 
the visualization of NeuN (Cy3) and with phase contrast.  
(B) The percentages of NeuN positive cells were determined by counting all positive labeled 
cells with granule cell shape in phase contrast and dividing them by the total number of 
DAPI-positive nuclei using Nikon software. Means are presented with SEM (n = 6). * p < 0,05 
compared to control. 
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